BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Azhar EI, Hindawi SI, El-Kafrawy SA, Hassan AM, Tolah AM, Alandijany TA, Bajrai LH, Damanhouri GA. Amotosalen and ultraviolet A light treatment efficiently inactivates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human plasma. Vox Sang 2021;116:673-81. [PMID: 33277935 DOI: 10.1111/vox.13043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Focosi D, Franchini M. Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency. Transfus Clin Biol 2021;28:132-4. [PMID: 33675992 DOI: 10.1016/j.tracli.2021.02.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Hindawi SI, El-Kafrawy SA, Hassan AM, Badawi MA, Bayoumi MM, Almalki AA, Zowawi HM, Tolah AM, Alandijany TA, Abunada Q, Picard-Maureau M, Damanhouri GA, Azhar EI. Efficient inactivation of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in human apheresis platelet concentrates with amotosalen and ultraviolet A light. Transfus Clin Biol 2021:S1246-7820(21)00119-1. [PMID: 34411748 DOI: 10.1016/j.tracli.2021.08.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Snyder EL, Wheeler AP, Refaai M, Cohn CS, Poisson J, Fontaine M, Sehl M, Nooka AK, Uhl L, Spinella P, Fenelus M, Liles D, Coyle T, Becker J, Jeng M, Gehrie EA, Spencer BR, Young P, Johnson A, O'Brien JJ, Schiller GJ, Roback JD, Malynn E, Jackups R, Avecilla ST, Lin JS, Liu K, Bentow S, Peng HL, Varrone J, Benjamin RJ, Corash LM. Comparative risk of pulmonary adverse events with transfusion of pathogen reduced and conventional platelet components. Transfusion 2022. [PMID: 35748490 DOI: 10.1111/trf.16987] [Reference Citation Analysis]
4 Tolah AM, Altayeb LM, Alandijany TA, Dwivedi VD, El-Kafrawy SA, Azhar EI. Computational and In Vitro Experimental Investigations Reveal Anti-Viral Activity of Licorice and Glycyrrhizin against Severe Acute Respiratory Syndrome Coronavirus 2. Pharmaceuticals (Basel) 2021;14:1216. [PMID: 34959616 DOI: 10.3390/ph14121216] [Reference Citation Analysis]
5 Vuk T, Hećimović A, Jukić I, Ravlić S, Kurtović T, Rnjak D, Halassy B. COVID-19 convalescent plasma therapy for immunodeficient patients-weighing up risks and benefits. Transfus Clin Biol 2021:S1246-7820(21)00083-5. [PMID: 34172379 DOI: 10.1016/j.tracli.2021.06.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Santa Maria F, Huang YS, Vanlandingham DL, Bringmann P. Inactivation of SARS-CoV-2 in All Blood Components Using Amotosalen/Ultraviolet A Light and Amustaline/Glutathione Pathogen Reduction Technologies. Pathogens 2022;11:521. [DOI: 10.3390/pathogens11050521] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Fachini RM, Fontão-Wendel R, Achkar R, Scuracchio P, Brito M, Amaral M, Wendel S. The 4-Year Experience with Implementation and Routine Use of Pathogen Reduction in a Brazilian Hospital. Pathogens 2021;10:1499. [PMID: 34832654 DOI: 10.3390/pathogens10111499] [Reference Citation Analysis]
8 Franchini M, Baldanti F, Percivalle E, Ferrari A, Biasi P, Liumbruno GM, Glingani C. Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma. Transfus Clin Biol 2021:S1246-7820(21)00113-0. [PMID: 34391625 DOI: 10.1016/j.tracli.2021.07.006] [Reference Citation Analysis]
9 Alandijany TA, Faizo AA. Development of Serological Assays and Seroprevalence Studies of the New Coronavirus 2019 (COVID-19): Reports from Saudi Arabia. Healthcare (Basel) 2021;9:1730. [PMID: 34946456 DOI: 10.3390/healthcare9121730] [Reference Citation Analysis]